Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23601201 | 0.91 | GRM5 (0.36) | PDE5AABCG2MAPTSMN1; SMN2CSNK2A1 | |
| SCHEMBL29909000 | 0.90 | CYP1A1 (0.39) | PDE5AABCG2MAPTSMN1; SMN2CSNK2A1 | |
| SCHEMBL23577064 | 0.90 | CYP1A1 (0.39) | PDE5AABCG2MAPTSMN1; SMN2CSNK2A1 | |
| SCHEMBL23576696 | 0.89 | CYP1A2 (0.33) | PDE5AABCG2MAPTSMN1; SMN2 | |
| SCHEMBL29909301 | 0.89 | CYP1A2 (0.33) | PDE5AABCG2MAPTSMN1; SMN2 | |
| SCHEMBL29909682 | 0.88 | MAPT (0.34) | PDE5AABCG2MAPTSMN1; SMN2CSNK2A1 | |
| SCHEMBL23576669 | 0.88 | MAPT (0.34) | PDE5AABCG2MAPTSMN1; SMN2CSNK2A1 | |
| SCHEMBL23600546 | 0.87 | ALOX15 (0.33) | PDE5AABCG2MAPTSMN1; SMN2CSNK2A1 | |
| SCHEMBL23577272 | 0.87 | ABCG2 (0.32) | PDE5AABCG2MAPTSMN1; SMN2CSNK2A1 | |
| SCHEMBL29909592 | 0.87 | ABCG2 (0.32) | PDE5AABCG2MAPTSMN1; SMN2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | PDE5A 1924/4885ABCG2 4216/4885MAPT 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.